SCHEMBL20417025

SCHEMBL20417025

N#Cc1cccc(-c2cc(-c3cn(Cc4cccc(N5CCCC5)n4)nn3)nc(NC3CC3)n2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 1/20 0.38
▸ HDAC2 Q92769 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ LRRK2 Q5S007 8/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ PRKD1 Q15139 1/20 0.35
▸ PRKD2 Q9BZL6 1/20 0.35
▸ PDE10A Q9Y233 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ADORA2B P29275 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ CYP19A1 P11511 1/20 0.35
▸ PIM1 P11309 1/20 0.34
▸ PDE4D Q08499 1/20 0.34
▸ PRKCQ Q04759 1/20 0.34
▸ MAP4K1 Q92918 1/20 0.34
▸ JAK2 O60674 1/20 0.34
▸ JAK1 P23458 1/20 0.34
▸ JAK3 P52333 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20436732 0.98 HDAC2 (0.36) CNR1HDAC2HDAC8HDAC6LRRK2
SCHEMBL20417003 0.92 CCNA2 (0.36) CNR1LRRK2PRKCQMAP4K1
SCHEMBL26217266 0.92 CCNA2 (0.36) CNR1LRRK2PRKCQMAP4K1
SCHEMBL20436733 0.90 CCNA2 (0.36) CNR1LRRK2PRKCQMAP4K1
SCHEMBL20436641 0.90 CCNA2 (0.36) CNR1LRRK2PRKCQMAP4K1
SCHEMBL20416673 0.88 CNR1 (0.38) CNR1HDAC2HDAC8HDAC6LRRK2
SCHEMBL20417139 0.88 PDE4A (0.36) HDAC2HDAC8HDAC6LRRK2MAPK14
SCHEMBL20436631 0.87 ADORA2A (0.40) HDAC2HDAC8HDAC6MAPK14ADORA2A
SCHEMBL20416648 0.87 ADORA2A (0.46) LRRK2ADORA2AADORA2BADORA1
SCHEMBL20436640 0.86 ADORA2A (0.37) CNR1HDAC2HDAC8HDAC6LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4310082-A2 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS Arcus Biosciences, Inc. (US) 2024-01-24 — — EP disclosed
WO-2018136700-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. (US) 2018-07-26 — — WO disclosed
Send feedback